Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Sermorelin

GHRH (1-29), GRF 1-29 NH2, Sermorelin acetate

Quick Stats
Studies 223
Trials 41
Score 1
1989 pubmed

Comparison of growth hormone releasing hormone therapy and growth hormone therapy in growth hormone deficiency.

Butenandt. O O; Staudt. B B

Key Findings

  • A single IV dose of GHRH spikes GH levels but the effect is short‑lived.
  • Long‑term twice‑daily GHRH injections failed to improve growth in most children.
  • Switching to daily rhGH led to consistent growth improvements in all participants.

Practical Outcomes

  • For DIY health enthusiasts, this study suggests that using sermorelin (GHRH) isn’t an effective way to boost growth or GH levels over time. Proven rhGH therapy works better, but it requires medical supervision. Therefore, sermorelin isn’t recommended as a stand‑alone protocol for growth or anti‑aging purposes.

Summary

In a small study of kids with growth‑hormone deficiency, a single injection of growth‑hormone‑releasing hormone (GHRH) briefly raised hormone levels, but giving it regularly didn’t help them grow. Switching to standard recombinant human growth hormone (rhGH) made all the kids grow faster. The researchers concluded GHRH isn’t useful for routine treatment of this condition.

Abstract

Seven children with growth hormone deficiency of hypothalamic origin responded to an i.v. bolus of growth hormone releasing hormone (GHRH) (1-29)-NH2 with a mean serum increase of 10.7 ng/ml growth hormone (GH) (range 2.5-29.3 ng/ml). Continuous s.c. administration of GHRH of 4-6 micrograms/kg twice daily for at least 6 months did not improve the growth rate in five of the patients. One patient increased his growth rate from 1.9 to 3.8 cm/year and another from 3.5 to 8.2 cm/year; however, the growth rate of the latter patient then decreased to 5.4 cm/year. When treatment was changed to recombinant human growth hormone (rhGH) in a dose of 2 U/m2 daily, given s.c. at bedtime, the growth rate improved in all patients to a mean of 8.5 cm/year (range: 6.2 to 14.6). Presently GHRH cannot be recommended for the routine therapy of children with growth hormone deficiency since a single daily dose of rhGH produced catch-up growth which GHRH therapy did not.

Study Information

Provider

pubmed

Year

1989

DOI

10.1007/bf00595894